DR REDDYS LABORATORIES LTD — Regulatory Filings 2021

Jan 11, 2021

•·· Dr.Reddy's �;•

Dr. Reddy's Laboratorioo Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India.

CIN: L85195TG1984PLC004507

Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com

January 11, 2021

Corporate Relationship Department BSE Limited Dalal Street, Fort Mumbai - 400 001 Fax Nos.: 022-22723121 / 22723719 / 22722037 I 22722039

National Stock Exchange of India Ltd. "Exchange Plaza" Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051 Fax Nos.: 022-26598120/ 26598237/ 26598238

Scrip Code: 500124

Scrip Code: DRREDDY-EQ

Dear Sirs,

Sub: Press Release

Please find enclosed a Press Release on "Dr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market."

This is for your information.

With regards,

==> picture [131 x 65] intentionally omitted <==

Encl: As above

• CC:- New York Stock Exchange Inc.(Stock Code :RDY) NSE IFSC Ltd

==> picture [492 x 48] intentionally omitted <==

DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India.

CONTACT INVESTOR RELATl0NS MEDIA RELATIONS AMIT AGARWAL APAHNA TEKURI �1r1ila@ufredtlys.com apara1.ekurltdri eddys.corn (PH: +91-40-49002135) (PH: +91-40- 49002446)

• • • I•• • • • • , • • • • • • • • • • • • • • • • • • • o • • • • • • • • • • • • • • • • • • , • • • • • • • • • • , • • • • • • • • • • , • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • t • • • • • • • • • • • • • ' ' • • • ' • ' • • • • • • • • • • • • • • • •, • • • • I • o •

Dr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market

Hyderabad, India. January 11, 2021

For Immediate Reloase

Hyderabad, India and Princeton, NJ, USA. January 11, 2021 - Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: ROY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets approved by the U.S. Food and Drug Administration (USFDA).

The Uloric brand and generic had U.S. sales of approximately $108 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health*.

Dr. Reddy's Febuxostat Tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets.

Please see the full prescribing information including boxed warning. hltps://w.drreddys,com/pi/febuxostal lablets.pdf

WARNING: CARDIOVASCULAR DEATH

Gout patients with established cardiovascular (CV) disease treated with Febuxostat had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study [see Warnings and Precautions (5.1 )].

Consider the risks and benefits of Febuxostat when deciding to prescribe or continue patients on Febuxostat. Febuxostat should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable [see Indications and Usage (1 )].

Uloric is a trademark of TEIJIN KABUSHIKI KAISHA (TEIJIN LIMITED) *IQVIA Retail and Non-Retail MAT October 2020. RDY-0121-323

About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: ROY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including AP ls, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dennatology. Dr. Reddy's operates in markets across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: w.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues .... and (vi) the susceptibility of our industry and the ma"'r�\ � addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings pa d ;\ -e 10 �o.,. Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" se.ctlon � ur II. al Report on Fann 20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contain rein • , 'a . o , ddy[s ] • • ,<, 'J, b ( <' �f